Skip Navigation

This Article
Right arrow Abstract
Right arrow FREE Full Text
Services
Right arrow Email this article to a friend
Right arrow Alert me to new issues of the journal
Right arrowRequest Permissions
Right arrow Disclaimer

The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis
Rheumatology Wilson et al. 46: 1096

Supplementary Data

files

Files in this Data Supplement:



This Article
Right arrow Abstract
Right arrow FREE Full Text
Services
Right arrow Email this article to a friend
Right arrow Alert me to new issues of the journal
Right arrowRequest Permissions
Right arrow Disclaimer